Skip to main content
Springer Nature Link
Log in

Significant association between cytotoxic T lymphocyte antigen 4 +49G>A polymorphism and risk of malignant bone tumors

  • Research Article
  • Published:
Tumor Biology

Abstract

Cytotoxic T lymphocyte antigen 4 (CTLA-4) gene +49G>A polymorphism was implicated to be associated with risk of malignant bone tumors, but the finding was inconclusive owing to the limited sample of a single study. The objective of the current study was to conduct a pooled analysis of four previously published studies to investigate the association between CTLA-4 +49G>A polymorphism and the risk of malignant bone tumors. Data were extracted, and the pooled odds ratio (OR) with the corresponding 95 % confidence interval (95 % CI) was calculated to assess the association. Those four published studies included a total of 2,165 subjects. The pooled results indicated that CTLA-4 +49G>A polymorphism was significantly associated with risk of malignant bone tumors (AA versus GG: OR = 2.24, 95 % CI 1.67–2.99, P < 0.001; AA/GA versus GG: OR = 1.35, 95 % CI 1.14–1.61, P = 0.001; AA versus GG/GA: OR = 2.00, 95 % CI 1.53–2.62, P < 0.001). Stratified analyses by tumor type showed that CTLA-4 +49G>A polymorphism was associated with risks of both osteosarcoma (AA versus GG: OR = 2.23, 95 % CI 1.45–3.43, P < 0.001; AA/GA versus GG: OR = 1.35, 95 % CI 1.04–1.75, P = 0.024; AA versus GG/GA: OR = 2.00, 95 % CI 1.34–2.98, P = 0.001) and Ewing's sarcoma (AA versus GG: OR = 2.24, 95 % CI 1.51–3.31, P < 0.001; AA/GA versus GG: OR = 1.36, 95 % CI 1.07–1.72, P = 0.011; AA versus GG/GA: OR = 2.01, 95 % CI 1.39–2.89, P < 0.001). Therefore, results from the current pooled analysis suggest that CTLA-4 +49G>A polymorphism is associated with risk of malignant bone tumors, including osteosarcoma and Ewing's sarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol. 2010;11:184–92.

    Article  PubMed  CAS  Google Scholar 

  2. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21 Suppl 7:vii320–5.

    PubMed  Google Scholar 

  3. Yarber JL, Agulnik M. Targeted therapies in bone sarcomas: current approach and future directions. Expert Opin Investig Drugs. 2011;20:973–9.

    Article  PubMed  CAS  Google Scholar 

  4. Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene. 2010;29:4504–16.

    Article  PubMed  CAS  Google Scholar 

  5. Schwab JH, Springfield DS, Raskin KA, Mankin HJ, Hornicek FJ. What's new in primary bone tumors. J Bone Joint Surg Am. 2012;94:1913–9.

    Article  PubMed  Google Scholar 

  6. Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother. 2013;62:203–16.

    Article  PubMed  CAS  Google Scholar 

  7. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA. 2008;299:2423–36.

    Article  PubMed  CAS  Google Scholar 

  8. Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev. 2008;223:143–55.

    Article  PubMed  CAS  Google Scholar 

  9. Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, et al. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother. 2011;60:1137–46.

    Article  PubMed  CAS  Google Scholar 

  10. Sun T, Hu Z, Shen H, Lin D. Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation. Cancer Res. 2009;69:6011–4.

    Article  PubMed  CAS  Google Scholar 

  11. Benhatchi K, Jochmanova I, Habalova V, Wagnerova H, Lazurova I. CTLA4 exon1 A49G polymorphism in Slovak patients with rheumatoid arthritis and Hashimoto thyroiditis—results and the review of the literature. Clin Rheumatol. 2011;30:1319–24.

    Article  PubMed  Google Scholar 

  12. Ghaderi A. CTLA4 gene variants in autoimmunity and cancer: a comparative review. Iran J Immunol. 2011;8:127–49.

    PubMed  CAS  Google Scholar 

  13. Yang M, Sun T, Zhou Y, Wang L, Liu L, Zhang X, et al. The functional cytotoxic T lymphocyte-associated protein 4 49G-to-a genetic variant and risk of pancreatic cancer. Cancer. 2012;118:4681–6.

    Article  PubMed  CAS  Google Scholar 

  14. Liu Y, He Z, Feng D, Shi G, Gao R, Wu X, et al. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 2011;30:1051–5.

    Article  PubMed  CAS  Google Scholar 

  15. Wang W, Wang J, Song H, Liu J, Song B, Cao X. Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma. Genet Test Mol Biomarkers. 2011;15:503–6.

    Article  PubMed  CAS  Google Scholar 

  16. Yang S, Wang C, Zhou Y, Sun G, Zhu D, Gao S. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to Ewing's sarcoma. Genet Test Mol Biomarkers. 2012;16:1236–40.

    Article  PubMed  CAS  Google Scholar 

  17. Feng D, Yang X, Li S, Liu T, Wu Z, Song Y, et al. Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing's sarcoma. Genet Test Mol Biomarkers. 2013;17:458–63.

    Article  PubMed  CAS  Google Scholar 

  18. Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, et al. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/AKt axis. PLoS One. 2011;6:e26060.

    Article  PubMed  CAS  Google Scholar 

  19. Postel-Vinay S, Veron AS, Tirode F, Pierron G, Reynaud S, Kovar H, et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet. 2012;44:323–7.

    Article  PubMed  CAS  Google Scholar 

  20. Mackintosh C, Ordonez JL, Garcia-Dominguez DJ, Sevillano V, Llombart-Bosch A, Szuhai K, et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene. 2012;31:1287–98.

    Article  PubMed  CAS  Google Scholar 

  21. Silva DS, Sawitzki FR, De Toni EC, Graebin P, Picanco JB, Abujamra AL, et al. Ewing's sarcoma: analysis of single nucleotide polymorphism in the EWS gene. Gene. 2012;509:263–6.

    Article  PubMed  CAS  Google Scholar 

  22. Attia J, Thakkinstian A, D’Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297–303.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interests

None.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, No. 98 Hospital of PLA, No.9 Chezhan Road, Huzhou, 313000, China

    Fengbin Yu

  2. Department of Orthopaedic Surgery, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200003, China

    Jinhao Miao

Authors
  1. Fengbin Yu
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Jinhao Miao
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Fengbin Yu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, F., Miao, J. Significant association between cytotoxic T lymphocyte antigen 4 +49G>A polymorphism and risk of malignant bone tumors. Tumor Biol. 34, 3371–3375 (2013). https://doi.org/10.1007/s13277-013-0908-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-0908-7

Keywords